Austedo's drug class is a vmat2 inhibitor (vesicular monoamine transporter 2 inhibitor) What is tardive dyskinesia (td) and chorea associated with huntington’s disease The most common adverse reactions for austedo (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia The findings were presented at the 2025 neuroscience education institute fall congress. Austedo standard and xr tablets are currently indicated for adults for the treatment of chorea in huntington disease and tardive dyskinesia Austedo is the first vmat2 inhibitor approved by the us food and drug administration for adults with tardive dyskinesia
3 it is not currently approved for pediatric patients In a significant advancement for those suffering from tardive dyskinesia (td), the u.s This approval brings a new, convenient treatment option for patients grappling with this often debilitating condition Reduce involuntary movements with austedo xr® (deutetrabenazine) tablets treatment for td See safety info and boxed warning. In a cohort of 27 participants, up to 77% reported enhancements in daily activities such as speech and eating after three months of treatment.
WATCH
